Matthew K. Fust - Sep 14, 2023 Form 3 Insider Report for Neumora Therapeutics, Inc. (NMRA)

Role
Director
Signature
/s/ Joshua Pinto, as Attorney-in-Fact for Matthew K. Fust
Stock symbol
NMRA
Transactions as of
Sep 14, 2023
Transactions value $
$0
Form type
3
Date filed
9/14/2023, 06:57 PM
Previous filing
Jun 21, 2023
Next filing
Mar 11, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding NMRA Stock Option (Right to Buy) Sep 14, 2023 Common Stock 3.78K $8.32 Direct F1, F2
holding NMRA Stock Option (Right to Buy) Sep 14, 2023 Common Stock 8.01K $8.79 Direct F1, F2
holding NMRA Stock Option (Right to Buy) Sep 14, 2023 Common Stock 95.6K $2.52 Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares subject to the option are fully vested and exercisable.
F2 Reflects a 1-for-7.8463 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement on September 8, 2023.
F3 1/36th of the shares subject to the option vest on each monthly anniversary measured from December 23, 2020 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the third anniversary of the Vesting Commencement Date.

Remarks:

Exhibit 24 - Power of Attorney